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Role of biochemical markers of bone turnover as prognostic
indicator of successful osteoporosis therapy
Abstract
Most of the currently available anti-osteoporosis medications promptly and significantly influence the rate of bone turnover. Biochemical markers
of bone turnover now provide a high sensitivity to change, allowing the detection of these bone turnover changes within a couple of weeks. Since the
anti-fracture efficacy of inhibitors of bone resorption or stimulators of bone formation appears to be largely independent of baseline bone turnover,
biochemical markers do not appear to play a significant role in the selection of one particular drug, for an individual patient. However, there are
consistent data showing that short-term changes in biochemical markers of bone turnover may be significant predictors of future changes in bone
mineral density or fracture reduction, hence suggesting that bone turnover markers play a significant role in the monitoring of anti-osteoporosis
therapy.
© 2008 Elsevier Inc. All rights reserved.
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Introduction
Clinical trials, conducted since the early nineties, have un-
equivocally shown the ability of several anti-osteoporosis medi-
cations to reduce fracture occurrence at various skeletal sites,
including but not exhaustively the spine and hip [1].Whereas the
operational definition of osteoporosis is still based on a low bone
mineral density (BMD), because low BMD is known to con-
tribute to increased fracture risk, changes in bone mass and
density, in response to anti-resorptive therapy, account for only a
small portion of the predicted fracture risk reduction [2], a
picture which may, however, be significantly changed with the
availability of new therapies stimulating bone formation [3] or
uncoupling bone formation from bone resorption [4].
During the last decade, biochemical markers of bone turn-
over (BTM) have been developed, that are more sensitive than
conventional ones for detecting abnormalities or changes of
bone turnover rate [5]. Increased levels of bone resorption, and
short-term changes in BTM, have been shown to predict the risk
of fracture, independently of the level of BMD in untreated
individuals [6,7].
Dynamic changes in bone turnover, estimated bymeasurement
of bone biochemical markers, such as breakdown products of type
I collagen and proteins secreted by osteoblasts and osteoclasts in
blood and urine, can also account for a major portion of anti-
fracture efficacy of anti-resorptive or bone-forming agents [8].
Most of the currently marketed anti-osteoporosis medications
induce prompt and significant changes in BTM.
Since BTM measurements are non-invasive, fairly inexpen-
sive and can be repeated often, it seems important to provide
some guidance about the role BTM can play to identify patients
with rapid bone loss, to aid in therapeutic decision-making and
to monitor therapeutic efficacy of various treatments.
Baseline BTM as prognosis of future osteoporosis therapy
One of the major applications of BTM in the field of osteo-
porosis is to detect high bone turnover in postmenopausal women.
This could allow identification of individuals who should be
preferentially targeted for prevention or curative therapy, as there
is strong evidence that the higher the bone turnover, the greater the
future bone loss and/or fracture risk [6].
From a theoretical point of view, it is also conceivable that
intervention strategies may differ between patients with various
degrees of bone turnover, at the time of diagnosis, i.e. a patient
presenting with high rates of bone resorption being optimally
treated with anti-resorptive agents, whereas an individual with
low remodelling rate expecting greater benefit from a bone-
forming agent [9].
However, whether the pretreatment (i.e. baseline) BTM
concentrations are predictive of a greater response to any of the
anti-osteoporotic drugs remains rather controversial.
In a post-hoc analysis of the Fracture Intervention Trial (FIT),
the pivotal study based on which alendronate was granted a mar-
keting authorization for the treatment of osteoporosis, alendronate
non-spine fracture efficacy was greater among women with high
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pretreatment N-terminal propeptide of type I collagen (P1NP)
(Table 1). For osteoporotic women in the lowest tertile of
pretreatment P1NP, the alendronate versus placebo relative hazard
for non-spine fracture was 0.88 (95%CI 0.65–1.21) compared to a
relative hazard of 0.54 (95% CI 0.39–0.74) among those in the
highest tertile of P1NP. Similar results were observed among
women without osteoporosis at baseline.
However, the relationship between tertile of bone-specific
alkaline phosphatase (BALP) or C-terminal cross-linked telo-
peptide of type I collagen (sCTX) and the risk of non-spine
fracture did not reach statistical significance. There was no
relationship between pretreatment P1NP, BALP or sCTX and
alendronate efficacy or incident spine fracture among osteo-
porotic women [10]. Based on the assumption that alendronate
may reduce incident non-vertebral fracture to a greater degree in
non-osteoporotic women, with high compared to low bone
turnover, a recent pharmacoeconomic study (Markov model)
concluded that measurement of BTM has the potential to iden-
tify a subset of postmenopausal women (top BTM quartile),
without osteoporosis by BMD criteria, for whom alendronate
therapy to prevent fracture is cost-effective (costs per QALY
gained at 34,000 USD and 50,000 USD for women age 70
with high bone turnover and femoral neck BMD T-score of −2.0
and −1.5 respectively) [11].
A similar analysis of the risedronate phase III clinical pro-
grammes used the excretion of urinary deoxypyridinoline (DPD)
as an index of pretreatment bone resorption rates. During the first
year of treatment, women with high DPD (above premenopausal
normative median) gained lumbar spine BMD at a faster rate than
patients with lowDPD. The risedronate-mediated reduction in the
incidence of vertebral fractures was independent of baselineDPD.
However, the number needed-to-treat (NNT) to avoid one ver-
tebral fracture at 12 months was 15 in the group of patients with
highDPD and 25 in patients with lowDPD, an observation which
is not unexpected, based on the influence of the prevalent abso-
lute risk on NNT calculation [12]. The authors concluded that
although the reduction in overall fracture risk seems to occur
independent of baseline bone turnover, patient stratification by
pretreatment bone resorption rate seems tomake some sense from
a pharmacoeconomic point of view [9,12].
Little is known about how the baseline levels of BTM relate
to the densitometric response or the anti-fracture efficacy of
anabolic therapy in postmenopausal women. A post-hoc ana-
lysis of the Fracture Prevention Trial (FPT), the study which
demonstrated vertebral and non-vertebral fracture reductionwith
the recombinant human parathyroid hormone rhPTH (1–34)
(teriparatide), assessed the correlation between BTM and BMD
responses. Bone turnover status at baseline correlated signifi-
cantly with subsequent BMD responses. The highest correlation
was found with the changes in lumbar BMD observed after
18 months for teriparatide treatment. All correlations with BTM
were significant and positive and from largest to smallest, with
P1NP, urinary N-terminal telopeptide of type I collagen (uNTX),
serum carboxy-terminal extension peptide of procollagen type I
(P1CP), BALP and DPD. For femoral neck BMD changes, the
coefficients of correlation were of a much lower magnitude and
remained significant only for uNTX and DPD [13]. In another
study assessing the relationship between levels of baseline
turnover before PTH (1–84) and the subsequent changes in area
and volumetric BMD, higher baseline P1NP levels were
associated with greater increase in areal BMD. Each standard
deviation (SD) increase in baseline P1NP was associated with an
additional 1.7% increase (95% CI 0.5−3.0) in spine BMD
(assessed by dual-energy X-ray absorpotiometry [DXA]) and a
1.2% increase (95% CI 0.4−2.0) in hip DXA BMD, after
12 months of PTH. Higher baseline BALP or sCTX levels were
also associated with greater 1-year increases in hip and spine
DXA BMD respectively. Neither baseline P1NP nor BALP were
significantly associated with 1-year changes in volumetric BMD
(by quantitative computerised tomography [QCT]). Higher
baseline sCTX levels were associated with greater 1-year
increases in trabecular spine and cortical hip BMD QCT [14].
The association between pretreatment BTMconcentration and the
absolute and relative risks of vertebral and non-vertebral fractures
(FPT of teriparatide) was evaluated after adjusting for baseline
femoral neck BMD, number of prevalent fractures and age.
Higher pretreatment concentrations of BALP, P1NP, NTX and
DPD were associated with a greater risk of fracture. Teriparatide
significantly reduced the risk, regardless of pretreatment bone
turnover. For each BTM, the absolute risk of an osteoporotic
fracture was greatest in the highest tertile, while the relative risk
was not associated with baseline bone turnover. Hence, the NNT
to prevent a new osteoporotic fracture decreased as the BTM
concentration increased (from 10 to 7 for low to high P1NP tertile)
[15]. The authors concluded that teriparatide-mediated relative
fracture risk reduction was independent of pretreatment bone
turnover, which is supported by the absence of correlation bet-
ween baseline P1CP, DPD or uNTX and changes in structural and
dynamic bone parameters analysed from transiliac biopsy
specimens obtained during the same FPT [16].
Table 1
Summary of biochemical markers used in studies having assessed their role as predictor of response to anti-osteoporotic drug
Treatment Biochemical marker studied Outcome
Alendronate [10,17,18,19,20,21] Formation: BALP, PINP, PICP, OC Fracture, BMD
Resorption: sCTX, uNTX, DPD
Risedronate [12,22] Resorption: uDPD, uCTX, uNTX, Fracture, BMD
Teriparatide [13,14,15,33] Formation: BALP, PICP, PINP Fracture, BMD
Resorption: uDPD, uNTX, sCTX




Early changes in BTM to monitor anti-osteoporosis therapy
Similar to most chronic diseases, monitoring the efficacy of
treatment of osteoporosis is a challenge. In contrast to BMD,
which typically changes in response to therapy less than 2–5%
per year, or a maximum of 3% in 3–6 months, most of osteo-
porosis therapies act by reducing or increasing individual BTM
levels or their ratios by 30–200% within 3–6 months. Even
though BMD measurement is much more precise than BTM, it
is still easier to detect a 50% change with a BTM than a 3%
change in BMD with a DXA, after 3–6 months of therapy [8].
Generally, the ratio of signal to noise during the first year of
treatment is better for BTM than it is for BMD.
In early postmenopausal women receiving alendronate in the
prevention of osteoporosis (Early Postmenopausal Intervention
Cohort — EPIC study), change from baseline at month 6 in
uNTX or osteocalcin (OC) correlated with change from baseline
at month 24 in spine, hip and total body BMD. This corresponded
to a 4- to 5-fold greater increase at month 24 in BMD in the tertile
with the greatest decrease at month 6 in NTX or OC compared to
the tertile with the least decrease in the BTM. In this study, a
patient with a decrease of 40% for NTX or 20% for OC atmonth 6
had a 92% probability of a 2-year positive response in spine
BMD. In contrast, the poor specificity and negative predictive
value of these percentual cut-offs of BTM changes implied that a
change in NTX or OC above the cut-point was a poor predictor of
bone loss during alendronate treatment [17]. In a smaller cohort of
French osteoporotic women, the authors claimed, from observa-
tion of changes in BALP, OC, P1CP, P1NP, sCTX, uNTX, total
and free DPD after 4 months of alendronate, that sCTX, and to a
lesser extend, uNTX, were the best predictors of a significant gain
in spine BMDafter 1 year of therapy [18]. Early changes of uNTX
(3 months) were also shown to be good predictors of 12-month
lumbar spine BMD response to alendronate in Korean post-
menopausal women with osteoporosis [19]. Similar features were
reported for 6-month decreases in uNTX and DPD, as surrogate
for 2.5-year increases in hip, trochanter, spine and total BMD in
elderlyUSwomen [20]. The data from the FITwere used to assess
the relationship between changes in bone turnover after 1 year of
alendronate and subsequent hip, non-spine and spine fracture risk.
Each 1SD reduction in 1-year change in BALP was associated
with fewer spine (relative hazard [RH] 0.74, 95% CI 0.63–0.87),
non-spine (RH 0.89, 95% CI 0.78–1.00) and hip fracture (RH
0.61, 95% CI 0.46–0.78). Alendronate-treated women with at
least a 30% reduction in BALP had a lower risk of non-spine (RH
0.72, 95% CI 0.55–0.92) and hip fracture (RH 0.26, 95% CI
0.08–0.83) relative to those with reduction b30%. The authors
concluded that the association between early reduction in bone
turnover and long-term fracture reduction during alendronate
treatment was at least as strong as that observed with 1-year
changes in BMD [21].
Changes in the level of biochemical markers of bone resorp-
tion with risedronate treatment for osteoporosis were also exa-
mined as a surrogate for the decrease in fracture risk, in
osteoporotic patients from the risedronate vertebral fracture
trial. The reduction in urinary sCTX (median, 60%) and uNTX
(51%) at 3–6 months with risedronate therapy were significantly
associated (pb0.05) with the reduction in vertebral fracture risk
(75% over 1 year and 50% over 3 years). The changes in both
sCTX and uNTX accounted for approximately one-half (sCTX,
55%; uNTX, 49%) of the first year and approximately two-thirds
(sCTX, 67%; uNTX, 66%) over 3 years compared with placebo.
The changes in sCTX and uNTX accounted for 77% and 54%,
respectively, of risedronate effect in reducing the risk of non-
vertebral fractures over 3 years compared with placebo. The
relationships between vertebral fracture risk and changes from
baseline in sCTX and uNTX were not linear (pb0.05). In the
original publication [22] below a decrease of 55–60% for sCTX
and 35–40% for uNTX, the authors concluded that the decrease
in bone resorption in patients taking risedronate accounts for a
large proportion of the reduction in fracture risk but that there
was little further improvement in anti-fracture efficacy below a
decrease of 55–60% for sCTX and 35–40% for uNTX. [22]. The
data from this study were recently reanalysed by another team of
statisticians. The findings of the reanalysis still support the
original conclusion that there is a level of bone resorption below
which there is no fracture benefit, but this was only significant for
sCTX at a level of 51% decrease [23].
Whereas the relationship between BTM and BMD or frac-
ture reduction, in individual patients, has not yet been pub-
lished, for oral or intravenous ibandronate, the course of the
development of this bisphosphonate strongly support the value
of BTM as a surrogate for BMD or fracture assessment in
osteoporosis. The earliest studies conducted with ibandronate,
using suboptimal doses (1 and 0.5 mg IV given once every
3 months) resulted in marginal decreases in biochemical mar-
kers of bone resorption and formation, which eventually trans-
lated into small increases in spine BMD and insufficient
magnitude of fracture reduction to achieve statistical signifi-
cance [24]. By contrast, with continuous (2.5 mg daily) or
intermittent (20 mg every other days for 12 doses every
3 months) oral doses which were linked to a significant reduc-
tion in spinal fractures, similar to that seen with alendronate or
risedronate, the rate of bone turnover was reduced by 50–60%,
a magnitude also within the range observed with the oral effi-
cacious oral bisphosphonates [25]. For further clinical devel-
opment of ibandronate, the role of BTM, as predictor of efficacy
was even emphasised. Actually, a pharmacokinetic–pharmaco-
dynamic model, accurately describing the dose-dependent pre-
dicted urinary excretion of CTX, has surrogate of clinical
efficacy, was used to select the appropriate once-monthly dose
of ibandronate [26]. Clinical studies, showing the non-infe-
riority and/or superiority of the 150 mg monthly oral regimen,
on BMD, as compared to the daily 2.5 dose, the dose which
previously demonstrated anti-fracture efficacy [27] confirmed, a
posteriori, the interest of a pharmacostatistical model based on
BTM changes to predict the effect of a particular dosage of
ibandronate on hard end-points [28].
Data from randomized clinical studies of ibandronate, given
orally or intravenously, at different doses and for variable time
intervals to women with osteoporosis were examined to explore
the relationship between intermittent bisphosphonate therapy,
changes in bone resorption and fracture risk. The magnitude of
the reduction of the rate of bone resorption at the end of the
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drug-free interval rather than its fluctuation pattern after bis-
phosphonate administration determines anti-fracture efficacy,
provided that these fluctuations occur within the premenopausal
range [29]. From these results, the authors concluded that pro-
longation of the drug-free interval should be compensated by a
dose higher than the cumulative daily dose [29].
In the Multiple Outcomes of Raloxifene Evaluation (MORE)
trial, which demonstrated vertebral fracture reduction with
raloxifene, changes in OC and BALP, after 6 and 12 months,
were significantly related to future risk of vertebral fracture, also
after adjusting for baseline vertebral status and BMD. For a
decrease of 9.3 pg/l in OC after 1 year raloxifene therapy, the
odds ratio (OR) for a new vertebral fracture during 3 years was
0.69 (95% CI, 0.54–0.88). Similarly, for a decrease of 5.91 µg/l
in BALP, OR was 0.75 (95% CI, 0.62–0.92) [30]. After
adjustment of each significant baseline variable, in logistic
regression models using 1-year percent changes in BMD and
bone turnover and relevant baseline demographics to predict the
risk of vertebral fracture with raloxifene therapy at 3 years, the
percent changes in OC was better able to predict the reduction in
fracture risk than the percent changes in femoral neck BMD
[31]. When logistic regression analysis models were used to
evaluate the relationship between the changes at 1 year in P1NP,
OC, BALP, and urinary CTX and the risk of new vertebral
fractures at 3 years, in the same study, a 1-year decrease in
P1NP, BALP or OC but not urinary CTX was again predictive
of the 3-year vertebral fracture risk reduction with raloxifene.
The decrease in P1NP at 1 year accounted for 28% of the total
reduction in vertebral fracture risk [32].
Among all studied BTM in the teriparatide FPT, increases
in P1CP at 1 month and P1NP at 3 months correlated best with
increases in lumbar spine BMD at 18 months. The relationship
between these two BTM and the lumbar spine BMD response,
was stronger than the corresponding relationship for the fe-
moral neck BMD response [13]. Greater short-term changes in
P1NP during PTH (1–84) treatment were associated with grea-
ter 1-year increase in spine and hip BMD among postmeno-
pausal osteoporotic women. Each SD increase in the 3-month
change of P1NP was associated with a 21% greater increase in
QCT spine trabecular BMD [14]. When evaluating associations
between early changes in biochemical markers and structural
and dynamic bone parameters during teriparatide treatment,
changes in BALP at 1 month correlated with changes at
22 months in two-dimensional wall thickness, trabecular bone
volume, marrow star volume and trabecular thickness while
changes in P1CP at 1 month correlated with change in wall
thickness. Whereas no data are currently available to claim that
short-term changes in BTM during teriparatide are predictive of
future fracture reduction, the correlation of biochemical markers
of bone formation (but not resorption) with improvements of
bone structure indirectly support this hypothesis [16]. Based on
these results, an algorithm for using P1NP to monitor treatment
of patients with teriparatide was further developed [33]. Patients
with P1NP increases N10 µg/l after 1–3 months, were con-
sidered as responders while it was recommended that patients
with P1NP increases b10 µg/l should be assessed for adherence,
teriparatide administration and storage technique and for the
presence of medical conditions that might limit their therapeutic
response to teriparatide [33].
Conclusion
In conclusion, most of the currently available pharmacolo-
gical treatments for osteoporosis promptly and significantly
impact on the rate of bone turnover. BTM do not appear to be a
significant determinant in the selection of a particular anti-
osteoporosis drug. With the exception of a single and equivocal
study with alendronate, the anti-fracture efficacy of anti-osteo-
porosis agents appears to be largely independent of baseline
bone turnover. However, short-term changes in BTM reflecting
bone resorption (raloxifene, bisphosphonates) or bone forma-
tion (raloxifene, teriparatide, (1–84) parathyroid hormone) have
been consistently shown to predict future BMD changes (teri-
paratide, parathyroid hormone) or long-term fracture reduction
(alendronate, risedronate, raloxifene), strongly suggesting that
BTM could play a significant role in the monitoring of anti-
osteoporosis therapy. Further research should be stimulated to
assess the relevance of these findings to the care of individual
patients, i.e. how to define a response to a specific treatment
based on the short-term changes observed in BTM.
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